November 2022 Vol 13, No 11 | November 17, 2022
To examine how SEs impacting QOL in pts with ABC are perceived.
November 2022 Vol 13, No 11 | November 17, 2022
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
November 2022 Vol 13, No 11 | November 17, 2022
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
November 2022 Vol 13, No 11 | November 17, 2022
To assess OS at an updated cutoff with additional follow-up.
November 2022 Vol 13, No 11 | November 17, 2022
Here, we present the long-term follow-up data at up to 40 months.
November 2022 Vol 13, No 11 | November 17, 2022
Here, we present the primary analysis of the mBCC cohort.
November 2022 Vol 13, No 11 | November 17, 2022
MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, was evaluated (vs DAN) in a pivotal phase 3 study of MF patients previously treated with a JAK inhibitor (JAKi). This subgroup analysis evaluated MOMENTUM patients with baseline platelet counts ≤150 × 109/L.
November 2022 Vol 13, No 11 | November 17, 2022
To evaluate the epidemiology of upper GI morbidity, peptic ulcer risk, and prescription GARA use among patients with MCL or CLL/SLL and provide the nursing perspective on GARA use in oncology patient care.
Results 1 - 8 of 8